Compare CRF & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRF | MNKD |
|---|---|---|
| Founded | N/A | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1997 | 2004 |
| Metric | CRF | MNKD |
|---|---|---|
| Price | $6.10 | $3.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.69 |
| AVG Volume (30 Days) | 1.6M | ★ 3.0M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | N/A | $35.81 |
| Revenue Next Year | N/A | $11.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $6.30 | $2.23 |
| 52 Week High | $8.25 | $6.51 |
| Indicator | CRF | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 26.31 | 35.94 |
| Support Level | N/A | $3.30 |
| Resistance Level | $7.31 | $4.23 |
| Average True Range (ATR) | 0.08 | 0.16 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 21.28 | 3.03 |
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology, Health Care, Financials, Communication Services, Consumer Discretionary, Industrials, Exchange-Traded Funds, Utilities, Energy, Real Estate, and others.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.